{"data":{"id":4812,"citation":"Basit S., Ashraf Z., Lee K., Latif M.: First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK\/ROS1 cancer: Clinical and designing strategy update of lorlatinib. European Journal of Medicinal Chemistry, Volume 134, 2017","title":"First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK\/ROS1 cancer: Clinical and designing strategy update of lorlatinib","doi":"10.1016\/j.ejmech.2017.04.032","doi_url":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.04.032","pmid":null,"year":2017,"journal":"European Journal of Medicinal Chemistry","volume":"134","issue":null,"page":null,"authors":[{"first_name":"Sulman","last_name":"Basit","full_name":"Sulman Basit"},{"first_name":"Zaman","last_name":"Ashraf","full_name":"Zaman Ashraf"},{"first_name":"Kwangho","last_name":"Lee","full_name":"Kwangho Lee"},{"first_name":"Muhammad","last_name":"Latif","full_name":"Muhammad Latif"}],"url":"https:\/\/molmedb.upol.cz\/api\/v1\/publications\/4812","landing_page":"https:\/\/molmedb.upol.cz\/publication\/4812","created_at":"2026-06-22T14:35:17.000000Z","updated_at":"2026-06-22T14:35:17.000000Z"}}